NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for acute lymphoblastic leukemia


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Aileron Therapeutics Collaborators Publish In Vivo Research in Nature Showing Stapled Peptides Achieve the First Direct Inhibition of the Notch1 Transcription Factor Oncogene
2009 NOV 23 ... in Nature, Drs. Bradner and Verdine showed in multiple models, including T-cell acute lymphoblastic leukemia (T-ALL), that Stapled Peptides achieved tight direct binding to the Notch transcription ...
Subject: Aileron Therapeutics
Price: $3.00
*
ARIAD Reports Third Quarter 2009 Development Progress and Financial Results
2009 NOV 16 ... heavily pretreated patients with resistant and refractory CML and Philadelphia-positive acute lymphoblastic leukemia, including those with the T315I mutant variant of the target protein, BCR-ABL. ...
Subject: ARIAD Pharmaceuticals, Inc.
Price: $3.00
*
Data on acute lymphoblastic leukemia detailed by A.H. Goldstone and co-authors
2009 NOV 9 ... "The large MRC/ECOG Adult Acute Lymphoblastic Leukemia Study establishes the value of sibling donor allogeneic transplantation in patients with ...
Subject: Acute Lymphoblastic Leukemia
Price: $3.00
*
New myeloid leukemia study findings have been reported by researchers at Washington University
2009 NOV 16 ... with imatinib-resistant and -intolerant CML and Philadelphia chromosome-positive acute lymphoblastic leukemia. Nilotinib, an analog of imatinib, more potent than its parent compound, is another ...
Subject: Myeloid Leukemia
Price: $3.00
*
Reports outline acute lymphoblastic leukemia therapy research from Virginia Commonwealth University, Massey Cancer Center
2009 NOV 2 ... Scientists discuss in 'MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM' new findings in...
Subject: Acute Lymphoblastic Leukemia Therapy
Price: $3.00
*
Research from O. Lin and co-researchers in the area of lymphoblastic lymphoma described
2009 NOV 23 ... PA 19106-3621, USA. Keywords: City:Box, State:NY, Country:United States, Acute Lymphoblastic Leukemia, Diagnostics, Enzymes, Ewing Sarcoma, Hematology, Lymphoblastic Lymphoma, Oncology, ...
Subject: Lymphoblastic Lymphoma
Price: $3.00
*
Research from T. Palomero and co-authors in the area of acute lymphoblastic leukemia published
2009 NOV 9 ... in Clinical Lymphoma & Myeloma (Therapeutic Targeting of NOTCH1 Signaling in T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma & Myeloma, 2009;9(Suppl. 3):S205-S210). For additional ...
Subject: Acute Lymphoblastic Leukemia
Price: $3.00
*
Research from Toho University in membranous nephropathy provides new insights
2009 NOV 16 ... 5 months after allogeneic bone marrow transplantation from an unrelated donor for acute lymphoblastic leukemia," scientists in Chiba, Japan report. "His renal biopsy showed membranous ...
Subject: Membranous Nephropathy
Price: $3.00
*
Researchers 'notch' a victory toward new kind of cancer drug
2009 NOV 27 ... damaged, or mutated, in patients with a form of blood cancer, known as T-ALL or T-cell acute lymphoblastic leukemia.Abnormal NOTCH genes found in cancer patients remain in a state of constant ...
Subject: Broad Institute of Mit and Harvard
Price: $3.00
*
Researchers at University Autonoma of Nuevo Leon, Department of Hematology publish new data on acute lymphoblastic leukemia in children
2009 NOV 23 ... determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia,' is now available. According to recent research published in the journal Leukemia & ...
Subject: Acute Lymphoblastic Leukemia
View Free
Daily News
Article
Researchers from Catholic University of Korea describe findings in acute lymphoblastic leukemia therapy
2009 NOV 2 ... stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study,' are detailed in a study ...
Subject: Acute Lymphoblastic Leukemia Therapy
Price: $3.00
*
Scientists at University of Tehran, Medical Imaging Center publish new data on acute lymphoblastic leukemia
2009 NOV 16 ... According to a study from Iran, "Acute lymphoblastic leukemia (ALL) presenting with musculoskeletal pain may be difficult to distinguish from juvenile ...
Subject: Acute Lymphoblastic Leukemia
Price: $3.00
*
Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
2009 NOV 9 ... their offering. The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few ...
Subject: Research and Markets
Price: $3.00
*
Stars of Film, Television, Sports and Music Join Marlo Thomas to Kick Off the 6th Annual Thanks and Giving(R) Campaign to Support St. Jude Children's Research Hospital(R)
2009 NOV 16 ... to 80 percent overall. When St. Jude opened its doors in 1962, the survival rate for acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, was 4 percent. Today, the survival rate ...
Subject: Pediatrics
Price: $3.00
*
Studies conducted at Duke University on leukemia recently published
2009 NOV 9 ... W Harrison St., Chicago, IL 60612, USA. Keywords: United States, Durham, Acute Lymphoblastic Leukemia, Bone Marrow, Clinical Pathology, Cytometry, Hematology, Oncology, Residual Neoplasm, ...
Subject: Leukemia
Price: $3.00
*
Studies from D. Hoelzer and co-researchers yield new data on acute lymphoblastic leukemia
2009 NOV 9 ... to recent research published in the journal Clinical Lymphoma & Myeloma, "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, ...
Subject: Acute Lymphoblastic Leukemia
Price: $3.00
*
Studies from S.S. Gaundar and co-researchers yield new data on vascular endothelial growth factor
2009 NOV 9 ... bone marrow microenvironment provides critical support for the growth and survival of acute lymphoblastic leukemia cells and protection against the effects of chemotherapeutic agents. Although the ...
Subject: Vascular Endothelial Growth Factor
Price: $3.00
*
Studies in the area of acute lymphoblastic leukemia reported from University of Newcastle
2009 NOV 2 ... Kingdom, "We report 2 novel, cryptic chromosomal abnormalities in precursor B-cell acute lymphoblastic leukemia (BCP-ALL): a translocation, either t(X;14)(p22;q32) or t(Y;14)(p11;q32), in 33 patients ...
Subject: Acute Lymphoblastic Leukemia
Price: $3.00
*
Study data from A. Peter and co-authors update knowledge of acute lymphoblastic leukemia in children
2009 NOV 2 ... Investigators publish new data in the report 'Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number ...
Subject: Acute Lymphoblastic Leukemia
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login